News
-
April 30, 2020
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will report its first...
-
April 16, 2020- Rolling BLA Submission Initiated Under Breakthrough Therapy Designation
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the initiation of the rolling...
-
March 16, 2020- PROTECT Study Randomization to be Paused Temporarily in Response to the Ongoing Public Health Crisis
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced a temporary pause in the...
-
March 12, 2020- Expect to Complete Submission of a BLA for PRV-031 (Teplizumab) in Q4 2020
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the fourth...
-
March 12, 2020-PRV-3279 Inhibited the Function of B Cells, Durably and Without Depletion-
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced positive top-line results from...